Total Payments
$1,807
2024 Payments
$481.52
Companies
35
Transactions
84
Medicare Patients
5,426
Medicare Billing
$800,849
Payment Breakdown by Category
Food & Beverage$1,654 (91.5%)
Education$153.71 (8.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,654 | 79 | 91.5% |
| Education | $153.71 | 5 | 8.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $229.02 | 11 | $0 (2024) |
| Celgene Corporation | $183.41 | 2 | $0 (2024) |
| Genentech USA, Inc. | $160.88 | 8 | $0 (2023) |
| Janssen Biotech, Inc. | $148.65 | 5 | $0 (2024) |
| Exelixis Inc. | $125.01 | 7 | $0 (2024) |
| Daiichi Sankyo Inc. | $73.78 | 4 | $0 (2024) |
| PFIZER INC. | $63.08 | 3 | $0 (2024) |
| Incyte Corporation | $50.91 | 3 | $0 (2024) |
| ABBVIE INC. | $50.52 | 3 | $0 (2024) |
| GlaxoSmithKline, LLC. | $50.08 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $481.52 | 20 | Janssen Biotech, Inc. ($132.32) |
| 2023 | $408.51 | 22 | Novartis Pharmaceuticals Corporation ($80.26) |
| 2022 | $560.37 | 29 | Genentech USA, Inc. ($85.26) |
| 2021 | $175.58 | 11 | Exelixis Inc. ($49.92) |
| 2017 | $181.49 | 2 | Celgene Corporation ($161.98) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.69 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.99 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $27.12 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 07/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY | Food and Beverage | In-kind items and services | $10.89 | General |
| Category: Oncology | ||||||
| 06/05/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Education | In-kind items and services | $89.99 | General |
| Category: Oncology | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $31.07 | General |
| Category: Immunology | ||||||
| 05/28/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/09/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Oncology | ||||||
| 05/09/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $10.44 | General |
| Category: Oncology | ||||||
| 04/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: ONCOLOGY | ||||||
| 04/10/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: HEMATOLOGY | ||||||
| 03/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: ONCOLOGY | ||||||
| 03/19/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Oncology | ||||||
| 02/29/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: IMMUNOLOGY | ||||||
| 02/06/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $21.43 | General |
| Category: Hematology | ||||||
| 01/30/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $19.20 | General |
| Category: Hematology/Oncology | ||||||
| 01/24/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Oncology | ||||||
| 01/11/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 01/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Oncology | ||||||
| 01/03/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Emmaus Medical, Inc. | Endari (Drug) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Sickle Cell | ||||||
| 11/03/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: Oncology | ||||||
| 10/31/2023 | Amgen Inc. | Blincyto (Biological), Kyprolis | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Oncology | ||||||
| 10/19/2023 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: HEMATOLOGY | ||||||
| 09/20/2023 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 1,553 | 42,583 | $1.2M | $336,917 |
| 2022 | 47 | 1,918 | 61,785 | $1.1M | $289,081 |
| 2021 | 28 | 1,301 | 3,453 | $367,717 | $114,996 |
| 2020 | 13 | 654 | 1,137 | $197,407 | $59,855 |
Total Patients
5,426
Total Services
108,958
Medicare Billing
$800,849
Procedure Codes
116
All Medicare Procedures & Services
116 procedure records from CMS Medicare Utilization — Page 4 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 90 | 245 | $55,811 | $24,408 | 43.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 199 | 279 | $68,568 | $22,121 | 32.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 11 | 960 | $48,960 | $16,190 | 33.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 183 | 213 | $39,484 | $12,101 | 30.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 15 | 70 | $26,460 | $7,937 | 30.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 39 | 39 | $13,423 | $4,360 | 32.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 27 | 27 | $12,645 | $4,236 | 33.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 46 | $20,700 | $3,674 | 17.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 115 | 394 | $11,426 | $3,061 | 26.8% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 13 | 38 | $7,828 | $2,431 | 31.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 107 | 215 | $8,385 | $2,270 | 27.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 16 | 38 | $7,068 | $2,172 | 30.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 14 | $6,826 | $1,493 | 21.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 20 | 114 | $7,638 | $1,296 | 17.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 17 | 23 | $7,590 | $1,277 | 16.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 135 | 383 | $3,447 | $1,149 | 33.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 16 | 16 | $4,317 | $757.59 | 17.5% |
| 82728 | Ferritin (blood protein) level | Office | 2021 | 40 | 55 | $2,750 | $749.65 | 27.3% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 16 | 30 | $1,590 | $541.20 | 34.0% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 23 | 25 | $4,250 | $505.57 | 11.9% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2021 | 25 | 27 | $1,512 | $407.16 | 26.9% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2021 | 13 | 22 | $1,496 | $404.58 | 27.0% |
| 83550 | Iron binding capacity | Office | 2021 | 33 | 40 | $1,280 | $349.60 | 27.3% |
| 83540 | Iron level | Office | 2021 | 34 | 43 | $1,032 | $278.21 | 27.0% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2021 | 32 | 45 | $1,035 | $271.80 | 26.3% |
About Dr. Gilberto Rodrigues, MD
Dr. Gilberto Rodrigues, MD is a Hematology healthcare provider based in Lake City, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700851243.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gilberto Rodrigues, MD has received a total of $1,807 in payments from pharmaceutical and medical device companies, with $481.52 received in 2024. These payments were reported across 84 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($1,654).
As a Medicare-enrolled provider, Rodrigues has provided services to 5,426 Medicare beneficiaries, totaling 108,958 services with total Medicare billing of $800,849. Data is available for 4 years (2020–2023), covering 116 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Internal Medicine
- Location Lake City, FL
- Active Since 02/20/2006
- Last Updated 07/06/2021
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1700851243
Products in Payments
- ERLEADA (Drug) $121.43
- CABOMETYX (Drug) $90.87
- KISQALI (Drug) $76.93
- Enhertu (Drug) $73.78
- VENCLEXTA (Drug) $50.52
- ZEJULA (Drug) $50.08
- MONOFERRIC (Drug) $48.58
- PROMACTA (Drug) $45.55
- FEMARA (Drug) $44.22
- Vonjo (Drug) $38.47
- Tecentriq (Biological) $37.07
- Trodelvy (Drug) $35.77
- OXBRYTA (Drug) $34.39
- JAKAFI (Drug) $31.40
- Fabhalta (Drug) $31.07
- IBRANCE (Drug) $28.69
- IMBRUVICA (Drug) $28.47
- DARZALEX (Biological) $27.22
- Rezlidhia (Drug) $27.12
- Kadcyla (Biological) $26.97
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.